Affordable Access

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.

Authors
  • Cassetti, Isabel
  • Madruga, José Valdez R
  • Suleiman, Jamal Muhamad A H
  • Etzel, Arnaldo
  • Zhong, Lijie
  • Cheng, Andrew K
  • Enejosa, Jeffrey
Type
Published Article
Journal
HIV clinical trials
Publication Date
Jan 01, 2007
Volume
8
Issue
3
Pages
164–172
Identifiers
PMID: 17621463
Source
Medline
License
Unknown

Abstract

Through 288 weeks, once-daily TDF+3TC+EFV demonstrated sustained antiretroviral activity with continued immunologic recovery. TDF treatment was not associated with renal adverse events or limb fat loss in antiretroviral-naïve patients.

Report this publication

Statistics

Seen <100 times